PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment

(2020) Hiro Sato et al.   International Journal of Clinical Oncology

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers

(2020) Hiroto Takeuchi et al.   Frontiers in Veterinary Science

Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma

(2019) Kim Wong et al.   Nature Communications

Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases

(2019) Dennis P. O’Malley et al.   MODERN PATHOLOGY

Safety, Clinical Activity, and Biological Correlates of Response in Patients With Metastatic Melanoma: Results From a Phase I trial of Atezolizumab

(2019) Omid Hamid et al.   CLINICAL CANCER RESEARCH

Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison

(2019) Prouteau et al.   Genes

Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes

(2019) Guifang Guo et al.   Journal for ImmunoTherapy of Cancer

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

(2019) Jong Yeob Kim et al.   Cancers

Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms

(2018) Christina Koppel et al.   MODERN PATHOLOGY

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Serum C-reactive protein is an important and powerful prognostic biomarker in most adult solid tumors

(2018) Shiva Shrotriya et al.   PLoS One

Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis

(2018) William P. D. Hendricks et al.   PLoS Genetics

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

(2017) Narek Shaverdian et al.   LANCET ONCOLOGY

Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients

(2017) Jarrett J. Failing et al.   MELANOMA RESEARCH

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors

(2017) S. R. Kumar et al.   Veterinary and Comparative Oncology

PD-1 expression by canine T cells and functional effects of PD-1 blockade

(2017) J. Coy et al.   Veterinary and Comparative Oncology

A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma

(2017) Naoya Maekawa et al.   Scientific Reports

Immune regulation of canine tumour and macrophage PD-L1 expression

(2016) G. Hartley et al.   Veterinary and Comparative Oncology

Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1

(2016)   Veterinary and Comparative Oncology

Dogs as a Model for Cancer

(2016) Heather L. Gardner et al.   Annual Review of Animal Biosciences

PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment

(2016) Andrew S. Flies et al.   Frontiers in Immunology

Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma

(2016) Naoya Maekawa et al.   PLoS One

Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006–2012)

(2015) Mifumi Kawabe et al.   JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Associated Macrophages: From Mechanisms to Therapy

(2014) Roy Noy et al.   IMMUNITY

Immunology of naturally transmissible tumours

(2014) Hannah V. Siddle et al.   IMMUNOLOGY

Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes

(2014) Ryoyo Ikebuchi et al.   IMMUNOLOGY

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade

(2014) Naoya Maekawa et al.   PLoS One

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer

(2013) M. Sznol et al.   CLINICAL CANCER RESEARCH

Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer

(2013) H. V. Siddle et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document

(2013) S. M. Nguyen et al.   Veterinary and Comparative Oncology

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

Interactions of host IL-6 and IFN-γ and cancer-derived TGF-β1 on MHC molecule expression during tumor spontaneous regression

(2008) Ya-Wen Hsiao et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY